Personalis Inc 2026年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) Delaware27-5411038(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)6600 Dumbarton CircleFremont, California94555(Address of principal executive offices)(Zip Code)Registrant’s telephone number, including area code:(650) 752-1300 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredThe Nasdaq Global Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reportingcompany☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ The number of shares of registrant’s Common Stock outstanding as of April 29, 2026 was 104,721,098. PERSONALIS, INC. Form 10-QFor the Quarterly Period Ended March 31, 2026 TABLE OF CONTENTS Item 1.Legal Proceedings34Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds74Item 3.Defaults Upon Senior Securities74Item 4.Mine Safety Disclosures74Item 5.Other Information74Item 6.Exhibits75Signatures76 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectivesof management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statementsbecause they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would” or the negative of these words or other similarterms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: •the evolution of cancer therapies and market adoption of our testing services;•estimates of our future revenue and the timing thereof, expenses, use of cash and other resources, cost savings,capital requirements, and our needs for additional financing and our ability to obtain financing when needed;•future reimbursement and reimbursement rulings and the timing thereof;•our business strategies, including our aim to focus on certain indications and the timing thereof;•the benefits of our testing services, including their ability to increase the probability of clinical trial success;•our ability to enter into and compete effectively in existing and new markets, with existing competitors and new marketentrants;•our ability to manage and grow our business by expanding our sales to existing customers or introducing our testingservices to new customers;•our sales, marketing and commercialization plans and strategies, including the expected benefits of and activities to beperformed under our Commercialization and Reference Laboratory Agreement with Tempus AI, Inc. ("Tempus");•our future business with the U.S. Department of Veterans Affairs' Million Veteran Program ("VA MVP"), ModernaTX,Inc. ("Moderna"), Merck & Co., Inc. ("Merck"), and other collaboration partners and customers;•our belief that approval of personalized cancer therapies by the U.S. Food and Drug Administration ("FDA") may drivebenefits to our business;•our ability to benefit from the scaling of our infrastructure and capacity at our headquarters facility in Fremont;•the impact our collaboration